Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s490, 2024. DOI: 10.25251/skin.8.supp.490. Disponível em: https://skin.dermsquared.com/skin/article/view/3136. Acesso em: 2 may. 2026.